ACS Medicinal Chemistry Letters
Letter
Parkinson’s disease treatment and dyskinesia. Neuropharmacology
2013, 66, 158−169.
Identification of potent, selective, and orally bioavailable agonists for
mGlu2/3 receptors. J. Med. Chem. 2007, 50, 233−40.
(8) Lopez, S.; Bonito-Oliva, A.; Pallottino, S.; Acher, F.; Fisone, G.
Activation of metabotropic glutamate 4 receptors decreases L-DOPA-
induced dyskinesia in a mouse model of Parkinson’s disease. J.
Parkinson’s Dis. 2011, 1, 339−346.
(9) Wieron
́
ska, J. M.; Stachowicz, K.; Pałucha-Poniewiera, A.; Acher,
F.; Branski, P.; Pilc, A. Metabotropic glutamate receptor 4 novel
́
agonist LSP1-2111 with anxiolytic, but not antidepressant-like activity,
mediated by serotonergic and GABAergic systems. Neuropharmacology
2010, 59, 627−634.
́
(10) Wieronska, J. M.; Stachowicz, K.; Acher, F.; Lech, T.; Pilc, A.
Opposing efficacy of group III mGlu receptor activators, LSP1-2111
and AMN082, in animal models of positive symptoms of
schizophrenia. Psychopharmacology 2012, 220, 481−494.
́ ́ ́
(11) Wieronska, J. M.; Acher, F. C.; Sławinska, A.; Gruca, P.; Łason-
Tyburkiewicz, M.; Papp, M.; Pilc, A. The antipsychotic-like effects of
the mGlu group III orthosteric agonist, LSP1-2111, involves 5-HT1A
signalling. Psychopharmacology 2013, 227, 711−725.
(12) Davis, M. J.; Iancu, O. D.; Acher, F. C.; Stewart, B. M.; Eiwaz M,
A.; Duvoisin, R. M.; Raber, J. Role of mGluR4 in acquisition of fear
learning and memory. Neuropharmacology 2013, 66, 365−372.
(13) Green, A. R.; Gabrielsson, J.; Fone, K. C. F. Translational
neuropharmacology and the appropriate and effective use of animal
models. Br. J. Pharmacol. 2011, 164, 1041−1043.
(14) Gabrielsson, J.; Green, A. R.; Van der Graaf, P. H. Optimising in
vivo pharmacology studiespractical PKPD considerations. J.
Pharmacol. Toxicol. Methods 2010, 61, 146−156.
(15) Di, L.; Rong, H.; Feng, B. Demystifying brain penetration in
central nervous system drug discovery. J. Med. Chem. 2013, 56, 2−12.
(16) Smith, D.; Di, L.; Kerns, E. H. The effect of plasma protein
binding on in vivo efficacy: misconceptions in drug discovery. Nat. Rev.
Drug Discovery 2010, 9, 929−939.
(17) In silico parameters calculated using MOE (Molecular Operating
system, 2012).
(18) Wager, T. T.; Chandrasekaran, R. Y.; Hou, X.; Troutman, M.
D.; Verhoest, P. R.; Villalobos, A.; Will, Y. Defining desirable central
nervous system drug space through the alignment of molecular
properties, in vitro ADME, and safety attributes. ACS Chem. Neurosci.
2010, 1, 420−434.
(19) Persson, M.; Løye, A. F.; Mow, T.; Hornberg, J. J. A high
content screening assay to predict human drug-induced liver injury
during drug discovery. J. Pharmacol. Toxicol. Methods 2013, 68, 302−
313.
(20) Broad binding counterscreen conducted at Cerep (www.cerep.
(21) Broad functional counterscreens conducted at Euroscreen
(22) Cremers, T. I.; de Vries, M. G.; Huinink, K. D.; van Loon, J. P.;
v d Hart, M.; Ebert, B.; Westerink, B. H.; De Lange, E. C. Quantitative
microdialysis using modified ultraslow microdialysis: direct rapid and
reliable determination of free brain concentrations with the
MetaQuant technique. J. Neurosci. Methods 2009, 178, 249−254.
(23) For experimental conditions and bioanalytical methods for
LSP1-2111 see Supporting Information.
(24) Rorick-Kehn, L. M.; Perkins, E. J.; Knitowski, K. M.; Hart, J. C.;
Johnson, B. G.; Schoepp, D. D.; McKinzie, D. L. Improved
bioavailability of the mGlu2/3 receptor agonist LY354740 using a
prodrug strategy: in vivo pharmacology of LY544344. J. Pharmacol.
Exp Ther. 2006, 316, 905−13.
(25) Triplett, J. W.; Hayden, T. L.; McWhorter, L. K.; Gautam, S. R.;
Kim, E.; Bourne, E. D. W. A. Determination of gallium concentration
in “blood-free” tissues using a radiolabeled blood marker. J. Pharm. Sci.
1985, 74, 1007−1009.
(26) Monn, J. A.; Massey, S. M.; Valli, M. J.; Henry, S. S.;
́
Stephenson, G. A.; Bures, M.; Herin, M.; Catlow, J.; Giera, D.; Wright,
R. A.; Johnson, B. G.; Andis, S. L.; Kingston, A.; Schoepp, D. D.
Synthesis and metabotropic glutamate receptor activity of S-oxidized
variants of (−)-4-amino-2-thiabicyclo-[3.1.0]hexane-4,6-dicarboxylate:
123
dx.doi.org/10.1021/ml400338f | ACS Med. Chem. Lett. 2014, 5, 119−123